Abstract
Impulse control disorders (ICDs) are a known side effect of dopamine replacement therapy in patients with Parkinson's disease (PD). They can have devastating consequences for patients and their families.
MeSH terms
-
Adult
-
Amantadine / adverse effects
-
Antiparkinson Agents / adverse effects*
-
Benzothiazoles / adverse effects
-
Carbidopa / adverse effects
-
Catechols / adverse effects
-
Disruptive, Impulse Control, and Conduct Disorders / chemically induced*
-
Drug Combinations
-
Female
-
Humans
-
Indans / adverse effects
-
Indoles / adverse effects
-
Levodopa / adverse effects
-
Male
-
Middle Aged
-
Neuroprotective Agents / adverse effects*
-
Parkinson Disease / drug therapy*
-
Pramipexole
-
Selegiline / adverse effects
Substances
-
Antiparkinson Agents
-
Benzothiazoles
-
Catechols
-
Drug Combinations
-
Indans
-
Indoles
-
Neuroprotective Agents
-
Stalevo
-
rasagiline
-
ropinirole
-
Selegiline
-
Levodopa
-
Pramipexole
-
Amantadine
-
Carbidopa